Yeon Hee Park
Quick facts
Phase 2 pipeline
- Physician's choice treatments group
- Ribociclib with fulvestrant
- Sacituzumab Govitecan with pegfilgrastim
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Related
- Sector hub: All tracked pharma companies